胆囊癌淋巴转移分子机制研究进展

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (8): 919-923.

胆囊癌淋巴转移分子机制研究进展

张林, 李茂岚, 李松岗, 吴文广, 刘颖斌

上海交通大学医学院附属新华医院普外科,上海 200092

收稿日期:2012-03-13 修回日期:2012-06-02 出版日期:2012-08-26 发布日期:2012-08-14
通讯作者: 刘颖斌,男,博士,教授,博士生导师,研究方向:消化道肿瘤基础与临床研究。Tel: 021-25077880 E-mail: laoniulyb@163.com
作者简介:张林,男,博士研究生,研究方向:消化道肿瘤基础与临床研究。Tel: 021-25077880 E-mail: 378081152@qq.com
基金资助:
国家自然科学基金资助(30972918);高等学校博士学科点专项科研基金资助(博导类20110073110086)

Progress of the molecular mechanisms research of gallbladder cancer lymphatic metastasis

ZHANG Lin, LI Mao-lan, LI Song-gang, WU Wen-guang, LIU Ying-bin

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received:2012-03-13 Revised:2012-06-02 Online:2012-08-26 Published:2012-08-14

摘要/Abstract

摘要： 胆囊癌是胆道系统常见的恶性肿瘤。影响胆囊癌手术预后的因素包括:侵袭深度,组织学分级,淋巴及周围神经浸润和淋巴结转移。淋巴转移是胆囊癌常见的转移方式,其分子机制目前仍不甚清楚。血管内皮生长因子-C (VEGF-C)/VEGF-D及其受体VEGFR-3能够促进淋巴管生成,在淋巴转移中起到重要作用;p16 基因通过突变和甲基化,可能使肿瘤细胞恶性程度增加,与肿瘤的侵袭及淋巴结转移密切相关;缺氧诱导因子-1α (hypoxia inducible factor 1α, HIF-1α)可能通过诱导VEGF-C/-D的表达而调节肿瘤淋巴管生成,促进肿瘤淋巴结转移;细胞外基质(extracellular matrix, ECM)的降解是肿瘤细胞进入淋巴管的必要条件,基质金属蛋白酶(matrix metalloproteinase, MMPs)家族中MMP-2与MMP-9通过降解细胞外基质,为肿瘤细胞进入淋巴管提供必要条件,可能与胆囊癌淋巴转移有关。

关键词: 胆囊癌, 淋巴转移, 分子机制

Abstract: Gallbladder cancer (GBC) is the most frequent biliary tract malignancy. Prognostic factors that influence the success of aggressive surgical therapy include depth of invasion, histologic grade, lymphatic or perineural invasion, and lymphatic metastasis. Lymphatic metastasis is a common way of metastasis. The molecular mechanism of lymphatic metastasis remains unclear. VEGF-C/VEGF-D and its receptor VEGFR-3 promote Lymphangiogenesis and play a key role in lymph node metastasis. p16 may increase the degree of malignancy, through mutation and methylation, which is related to lymphatic metastasis. Hypoxia inducible factor 1α (HIF-1α) induces the expression of VEGF-C/-D, promote Lymphangiogenesis and lymph node metastasis. In the gene family of matrix metalloproteinase (MMPs), MMP-2 and MMP-9 may be associated with the lymphatic metastasis, which can degradate extracellular matrix (ECM).

Key words: Gallbladder carcinoma, Lymphatic metastasis, Molecular mechanisms

中图分类号:

R966

张林, 李茂岚, 李松岗, 吴文广, 刘颖斌. 胆囊癌淋巴转移分子机制研究进展[J]. 中国临床药理学与治疗学, 2012, 17(8): 919-923.

ZHANG Lin, LI Mao-lan, LI Song-gang, WU Wen-guang, LIU Ying-bin. Progress of the molecular mechanisms research of gallbladder cancer lymphatic metastasis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 919-923.

参考文献

[1] 刘颖斌, 吴文广, 全志伟. 胆囊癌的靶向治疗[J]. 中国实用外科杂志, 2010, 30(7): 553-555.
[2] 刘颖斌, 王许安, 彭淑牖. 胆囊癌扩大根治术的意义和评价[J]. 中国实用外科杂志, 2008, 28(9): 718-720.
[3] Longatto-Filho A, Martins A, Costa SM, et al. VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels [J]. Pathol Res Pract, 2005, 201(2): 93-99.
[4] Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics [J]. Nat Med, 2001, 7(2): 186-191.
[5] Karnezis T, Shayan R, Caesar C, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium[J]. Cancer Cell, 2012, 21(2): 181-195.
[6] Yanagawa T, Shinozaki T, Watanabe H, et al. Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas [J]. Exp Cell Res, 2012, 318(7): 800-808.
[7] Tampouris AI, Kandiloros D, Giotakis I, et al. The role of the VEGF-C/-D/flt-4 autocrine loop in the pathogenesis of salivary neoplasms [J]. Pathol Res Pract, 2012, 208(3): 151-156.
[8] Choi JH, Oh YH, Park YW, et al. Correlation of vascular endothelial growth factor-D expression and VEGFR-3-Positive vessel density with lymph node metastasis in gastric carcinoma [J]. J Korean Med SCi, 2008, 23(4): 592-597.
[9] Thelen A, Scholz A, Benckert C, et al. VEGF-D Promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma [J]. Int J Caneer, 2008, 122(11): 2471-2481.
[10] 陈华, 应卫星, 李荣洲. 维生素K2与苯那普利诱导胃癌细胞凋亡及抑制血管生成的体外实验研究 [J]. 中国临床药理学与治疗学, 2011, 16(6): 621-626.
[11] 李映新, 李剑军, 周先丽, 等.广西尖吻蝮蛇毒K组分抗血管生成活性研究 [J]. 医药导报, 2011, 30(2): 157-159.
[12] Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy [J]. Biol Pharm Bull, 2011, 34(12): 1785-1788.
[13] Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis [J]. N Engl J Med, 2008, 358(2): 199-200.
[14] Riley E, Carloss H. Dramatic response to panitumumab and bevacizumab in metastatic gallbladder carcinoma[J]. Oncologist, 2011,16(5):e1-e2.
[15] Jiang L, Chen YL, She FF, et al. Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma [J]. Zhonghua Zhong Liu Za Zhi, 2010, 32(3): 190-195.
[16] Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types[J]. Science, 1994, 264(5157): 436-440.
[17] Hu SL, Kong XY, Cheng ZD, et al. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma [J]. Tumori, 2010, 96(5): 726-733.
[18] Fu ZJ, Ma ZY, Wang QR, et al. Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients[J]. Clin Exp Metastasis, 2008, 25(8): 887-892.
[19] Melck A, Masoudi H, Griffith OL, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer [J]. Ann Surg Oncol, 2007,14 (12): 3403-3411.
[20] Goto T, Mizukami H, Shirahata A, et al. Methylation of the p16 gene is frequently detected in lymphatic-invasive gastric cancer [J]. Anticancer Res, 2010, 30(7): 2701-2703.
[21] Choi HJ, Yun SS, Kim HJ, et al. Expression of p16 protein in gallbladder carcinoma and its precancerous conditions[J]. Hepatogastroenterology, 2010, 57(97): 18-21.
[22] Shi YZ, Hui AM, Li X, et al. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas[J]. Clin Cancer Res, 2000, 6(10): 4096-4100.
[23] Wang PP, Kong FP, Chen XQ, et al. HIF-1 signal pathway in cellular response to hypoxia[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2011, 40(5): 559-566.
[24] Giatromanolaki A, Sivridis E, Simopoulos C, et al. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas [J]. J Surg Oncol, 2006, 94(3): 242-247.
[25] Schoppmann SF, Fenzl A, Schindl M, et al. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer [J]. Breast Cancer Res Treat, 2006, 99(2): 135-141.
[26] Katsuta M, Miyashita M, Makino H, et al. Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer [J]. Exp Mol Pathol, 2005, 78(2): 123-130.
[27] Batmunkh E, Shimada M, Morine Y, et al. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma [J]. Int J Clin Oncol, 2010, 15(1): 59-64.
[28] Wu W, Wang R, Liu H, et al. Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry [J]. Med Oncol, 2009, 26(2): 117-123.
[29] 赵敏, 刘明强, 邹强. 胆囊癌中VEGF和MMP-2的表达及其相关性 [J]. 临床与实验病理学杂志, 2010, 26(3): 336-338.
[30] Yang S, Zhao Z, Wu R, et al. Expression and biological relationship of vascular endothelial growth factor-a and matrix metalloproteinase-9 in gastric carcinoma [J]. J Int Med Res, 2011, 39(6): 2076-2085.
[31] Luizon MR, Almeida Belo VD. Matrix metalloproteinase (MMP)-2 and MMP-9 polymorphisms and haplotypes as disease biomarkers [J]. Biomarkers, 2012,17(3): 286-288.